CSIMarket
 

Fortress Biotech Inc   (NASDAQ: FBIO)

Fortress Biotech Inc 's

Competitiveness




 

FBIO Sales vs. its Competitors Q2 2026



Comparing the current results to its competitors, Fortress Biotech Inc reported Revenue increase in the 2 quarter 2026 by 25.66 % year on year.
The sales growth was above Fortress Biotech Inc 's competitors' average revenue growth of 5.93 %, achieved in the same quarter.

List of FBIO Competitors

With a net margin of 3.22 % Fortress Biotech Inc reported lower profitability than its competitors.

More on FBIO Profitability Comparisons



Revenue Growth Comparisons




Net Income Comparison


Fortress Biotech Inc achieved net profit of $0.60 millions compared to a net loss of $-28.82 millions recorded in the same quarter a year ago.

<<  FBIO Stock Performance Comparisons


Fortress Biotech Inc 's Comment on Competition and Industry Peers


The company operates in the biotechnology and biopharmaceutical sectors, competing with commercial pharmaceutical and biotechnology firms, academic institutions, government agencies, and private and public research organizations. Competitors often possess greater financial resources and capabilities in product development, manufacturing, and marketing, including large pharmaceutical companies experienced in clinical testing and regulatory approval. Universities and research institutes also compete in research activities and the recruitment of scientific and clinical personnel. Additionally, smaller or early-stage companies may pose competition, particularly through partnerships with larger firms. Competitors are engaged in developing or acquiring pharmaceuticals, medical devices, and over-the-counter products targeting similar diseases and conditions, potentially introducing new products or delivery systems with therapeutic or cost advantages.



  

Overall company Market Share Q2 2026

Due to strong revenue growth of 25.66 % in Overall company Fortress Biotech Inc improved its market share, to approximately 0.03 %.


<<  More on FBIO Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Fortress Biotech Inc




Immuron Limited
Share Performance



+56.52%
Over The Past 5 Days



Immuron Limited
Profile

Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.

More about Immuron Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 6.765 mill. $ -5.216 mill.


Matinas Biopharma Holdings Inc
Share Performance



-76.61%
This Quarter



Matinas Biopharma Holdings Inc
Profile

Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.

More about Matinas Biopharma Holdings Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.166 mill. $ - mill. $ -7.309 mill.


Nucana Plc
Share Performance



+2.94%
30 Days



Nucana Plc
Profile

Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.

More about Nucana Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -61.553 mill.


Nektar Therapeutics
Share Performance



+25.26%
This Quarter



Nektar Therapeutics
Profile

Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.

More about Nektar Therapeutics's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,452.340 mill. $ 54.589 mill. $ -157.127 mill.


Nanoviricides inc
Share Performance



-25.83%
This Quarter



Nanoviricides inc
Profile

Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.

More about Nanoviricides inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 24.203 mill. $ - mill. $ -8.091 mill.

90 more competitors available

Sign in to see all competitors

Sources: Fortress Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Fortress Biotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.